The role of CD133 in drug resistance has been described through analysis of the ability of SP1049C—a pluronic-based micellar formulation of Doxorubicin that has demonstrated safety and efficacy in patients with advanced OAC and GEJA in a phase II trial–to deplete CD133+ CSCs and decrease cancer cell tumorigenicity in vivo (Alakhova et al., 2013). This evidence concerns the gene PROM1 and cancer.